John D. Scott, MD, MSc | Allergy and Infectious Diseases

Associate Professor

Department of Medicine, Division of Allergy & Infectious Diseases

Medical Director, Telehealth

Associate Medical Director, Liver Clinic, Harborview Medical Center

Sites of Practice:

Harborview Medical Center

University of Washington Medical Center

Faculty Information

Biography

Dr. Scott's research focuses on viral hepatitis and the use of telehealth technologies to improve care of patients with Infectious Disease issues. Dr. Scott has an active research program with novel antivirals and diagnostics, in partnership with pharmaceutical companies. Along with Public Health Seattle King County, he is working on a CDC-funded initiative to increase diagnosis, linkage to care and treatment of patients with hepatitis C.

In 2009, he launched Project ECHO in Washington State. This innovative telehealth program helps clinicians serving in rural and underserved areas with the evaluation and treatment of hepatitis C, HIV/AIDS and tuberculosis. In 2013, he became the first medical director for telehealth at the UW. Research has focused on creating innovative learning platforms, in partnership with Dr. David Spach and Dr. Nina Kim through HCV Online.

Honors:

AOA, Georgetown University School of Medicine

1997

Fellow, IDSA

2013

Seattle Met, Top Doctors

2014

Warren Featherstone Reid Award for Excellence in Health Care for Washington State

2015

Contact

Email:

jdscott@u.washington.edu

Phone:

(206) 744-3393

Mailing Address:

Harborview Medical Center

325 9th Ave

Box 359938

Seattle, WA 98104

Research & Clinical Interests

Research Interests:

Viral hepatitis
Infections in solid organ transplant recipients
Telemedicine

Clinical Interests:

Viral hepatitis
Infections in solid organ transplant recipients
Telemedicine

Publications

PubMed:

PubMed Bibliography

Publications:

Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014 Nov 15; 384(9956):1756-65
• PubMed Abstract ]

Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and HCC in patients with HIV infection. Hepatology. 2013; 57:249-57.
• PubMed Abstract

Scott JD, Unruh K, Catlin MC, et al. Project ECHO: A model for complex, chronic care in the pacific northwest of the United States. J Telemed Telecare. 2012; 18(8):481-4.
•PubMed Abstract

Coffin P, Scott JD, Sullivan S, Golden M. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012 May; 54(9):1259-71.
•PubMed Abstract

Schiffer JT, Scott JD, Corey L. Fighting a defiant virus. Nature Med. 2011; 17:253-4.
•Nature Medicine Abstract

Scott JD, Holte S, Urban T, Burgess C, Coppel E, Wang C, Corey L, McHutchison J, Goldstein D.; IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult to treat hepatitis C virus infection. J Infect Dis. 2011; 204:419-25.
• PubMed Abstract

Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: A systematic review. JAMA. 2007; 297:724-732.
• PubMed Abstract

Printer-friendly